

## Entitlement Offer to raise approximately \$10 million

### Key Points

- Non-renounceable entitlement offer to raise up to approximately \$10 million (before direct offer costs).
- Offer price of \$0.028 per new share, a 31.7% discount to the closing price of Chimeric shares on 24 October 2023.
- Following successful completion, this will provide for the continuing advancement of the Company's drug development program, with four ongoing clinical trials in cell therapy.
- All Directors intend to participate in the Offer.

### Entitlement Offer

Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric** or **Company**) intends to conduct an equity raising via a 2 for 3 non-renounceable entitlement offer of new fully paid ordinary shares in Chimeric (**New Shares**) to raise up to approximately \$10 million (**Entitlement Offer**).

The offer price for the Entitlement Offer will be \$0.028 per share (**Offer Price**). The Offer Price represents:

- a 21.8% discount to the theoretical ex-rights price (**TERP**)<sup>1</sup> of \$0.036;
- a 27.7% discount to the 5-day volume weighted average price (VWAP) of \$0.039, and
- a 31.7% discount to the last traded price of Chimeric shares on 24 October 2023 of \$0.041.

Under the Entitlement Offer, eligible shareholders will be able to subscribe for 2 new ordinary share in Chimeric for every 3 existing shares held at 7pm (Sydney time) on 30 October 2023 (**Record Date**) at the Offer Price (**Entitlements**).

---

<sup>1</sup> The theoretical ex-rights price of \$0.036 is calculated using Chimeric's closing price on 24 October 2023 assuming proceeds from the Entitlement Offer of \$10 million. TERP is the theoretical price at which shares should trade immediately after the ex-date for the Entitlement Offer assuming 100% take-up of the Entitlement Offer. TERP is a theoretical calculation only and the actual price at which shares trade immediately after the ex-date for the Entitlement Offer will depend on many factors and may not be equal to the TERP.



Bell Potter Securities Limited will act as Lead Manager to the Entitlement Offer (including any shortfall to the Entitlement Offer).

The Board intends to use the proceeds of the Entitlement Offer to fund and continue advancement of the Company's drug development programme with four ongoing clinical trials in cell therapy.

### **Entitlement Offer**

Eligible shareholders in Australia and New Zealand will be invited to participate in the Entitlement Offer which will open on 2 November 2023 and close at 5:00pm (Sydney time) on 20 November 2023.

Further details about the Entitlement Offer will be set out in the Entitlement Offer Information Booklet (**Information Booklet**), which Chimeric expects to lodge with ASX on 2 November 2023. The Information Booklet will also enclose personalised entitlement and acceptance forms.

Eligible shareholders can choose to take up all, part or none of their Entitlement.

The Entitlements are non-renounceable and will not be tradeable on ASX or otherwise transferable. Shareholders who do not take up their Entitlements will not receive any value for those Entitlements that they do not take up. Shareholders who are not eligible to receive Entitlements will not receive any value for the Entitlements they would have received had they been eligible.

The Entitlement Offer is not underwritten.

Up to approximately 356 million new ordinary shares in Chimeric will be issued as part of the Entitlement Offer. Shares issued under the Entitlement Offer will rank equally with existing shares.

The Entitlement Offer will include a top up facility under which eligible shareholders who take up their full Entitlement will be invited to apply for additional shares in the Entitlement Offer from a pool of those not taken up by other eligible shareholders. There is no guarantee that applicants under this top up facility will receive all or any of the shares they apply for under the facility.

Chimeric will notify shareholders as to whether they are eligible to participate in the Entitlement Offer. Eligible shareholders will receive the Information Booklet including a personalised entitlement and acceptance form which will provide further details of how to participate in the Entitlement Offer.

A presentation on the Entitlement Offer has been lodged with ASX today and is able to be downloaded from ASX's website, [www.asx.com.au](http://www.asx.com.au).



## Key dates<sup>2</sup>

Event	Date
Announcement of the Entitlement Offer	25 October 2023
Ex date	27 October 2023
Record Date for Entitlement Offer (7.00pm, Sydney time)	30 October 2023
Information Booklet and Entitlement and Acceptance Form despatched	2 November 2023
Entitlement Offer opens	2 November 2023
Entitlement Offer closes (5.00pm, Sydney time)	20 November 2023
New Shares quoted on a deferred settlement basis	21 November 2023
Announcement of results of the Entitlement Offer	27 November 2023
Allotment of New Shares issued under the Entitlement Offer	27 November 2023
Despatch of holding statements for New Shares issued under the Entitlement Offer	28 November 2023

The quotation of the New Shares is subject to approval from the ASX.

All dollar amounts are in Australian dollars unless otherwise indicated.

### For further information, please contact:

If you have questions about the Entitlement Offer, please contact the share registry, Boardroom Pty Ltd on 1300 737 760 (inside Australia) or +61 2 9290 9600 (outside Australia).

**Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.**

### Important information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to in this document have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.

This document may not be distributed or released in the United States.

<sup>2</sup>All dates are indicative only and subject to change. Chimeric reserves the right to withdraw or vary the timetable without notice or consultation with you, subject to the Corporations Act 2001 (Cth), ASX Listing Rules, and any other applicable laws.



This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Chimeric does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.